Trevi Therapeutics | 10-Q:季度报表
Trevi Therapeutics | 8-K:Trevi Therapeutics公布2024年第一季度财务业绩并提供业务最新情况
Trevi Therapeutics | ARS:年度报告
Trevi Therapeutics | DEFA14A:其他
Trevi Therapeutics | DEF 14A:股东委托书决议
Trevi Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Rosalind Advisors, Inc.(1.34%),Steven Salamon(1.34%)等
Trevi Therapeutics | 8-K:Trevi Therapeutics公布2023年第四季度和年终财务业绩并提供业务最新情况
Trevi Therapeutics | 10-K:年度报表
Trevi Therapeutics | S-8:员工福利计划证券登记
Trevi Therapeutics | 4:持股变动声明-高管 Simon Farrell
Trevi Therapeutics | 4:持股变动声明-高管 Galletta Christopher
Trevi Therapeutics | 4:持股变动声明-高管 Clark David J
Trevi Therapeutics | 4:持股变动声明-高管 GOOD JENNIFER L
Trevi Therapeutics | 4:持股变动声明-高管 SCIASCIA THOMAS
Trevi Therapeutics | 4:持股变动声明-高管 Delfini Lisa
Trevi Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Venrock Healthcare Capital Partners II, L.P.(9.99%),VHCP Co-Investment Holdings II, LLC(9.99%)等
Trevi Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Fairmount Funds Management LLC(0.0%),Peter Harwin(0.0%)等
Trevi Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Viking Global Investors LP(9.99%),Viking Global Opportunities Parent GP LLC(9.99%)等
Trevi Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Rubric Capital Management LP(8.90%),David Rosen(8.90%)
Trevi Therapeutics:2023财年三季报
暂无数据